The fibrotic diseases treatment market was valued at USD 6.23 Billion in 2025 and is expected to grow at a CAGR of 7.60%, reaching USD 12.96 Billion by 2035. The market is propelled by increasing research investments and the introduction of advanced antifibrotic drugs enhancing disease management. Expanding clinical trials targeting fibrotic pathways and the integration of precision medicine are expected to stimulate market expansion during the forecast period, supported by growing patient awareness and improved diagnostic capabilities.
Base Year
Historical Period
Forecast Period
Compound Annual Growth Rate
7.6%
Value in USD Billion
2026-2035
*this image is indicative*
Fibrotic diseases, such as idiopathic pulmonary fibrosis (IPF) and scleroderma, are characterized by severe organ fibrosis. Progressive fibrosis can result in the thickening or scarring of the tissue. According to a study published in BMC Pulmonary Medicine in February 2023, the rate of idiopathic pulmonary fibrosis (IPF) has been increasing over time. The study found that the yearly prevalence rate of IPF increased from 7.50 to 23.20 per 100,000 individuals, and the yearly incidence rate increased from 3.56 to 7.91 per 100,000 individuals. The rising number of patients afflicted with this condition will fuel the fibrotic diseases treatment market growth in the forecast period.
In September 2023 , Boehringer Ingelheim initiated the clinical development of its first-of-its-kind IL-11 inhibitor antibody, BI 765423, through a Phase 1 study. The objective of the trial was to evaluate the treatment's safety, tolerance, and pharmacokinetics in fibrotic diseases. According to preclinical studies, anti-IL-11 treatment had the potential to halt and even reverse fibrosis in various fibrotic diseases. To bolster its fibrotic disease portfolio, Boehringer Ingelheim also partnered with Enleofen Bio Pte Ltd, a biotechnology company based in Singapore. The development of promising therapeutics is projected to fuel the fibrotic diseases treatment market demand in the coming years.
Significant drivers for market growth also include the rise in strategic partnerships among the key market players. In addition, the increased healthcare expenditure and growing geriatric population as also expected to contribute to the market value in the forecast period.
Fibrotic Diseases Treatment Market Report and Forecast 2026-2035 offers a detailed analysis of the market based on the following segments:
Market Breakup by Treatment Type
The market segmentation by treatment type comprises medication, organ transplantation, and oxygen therapy, among others. Medication options aim to slow disease progression and reduce symptoms by targeting inflammation and fibroblast activation. Organ transplantation may be necessary when fibrosis irreversibly damages vital organs. Oxygen therapy helps manage respiratory symptoms in fibrotic lung diseases.
Market Breakup by Applications
On the basis of applications, the fibrotic diseases treatment market share includes idiopathic pulmonary fibrosis (IPF), hepatic cirrhosis, renal fibrosis, cutaneous fibrosis, and others. These diverse applications convey the scope of the treatment market across various organ systems.
Market Breakup by End User
End users of the market are hospitals, academic, and research institutes, among others. Academic and research institutes significantly contribute to the development of innovative treatments and therapeutic approaches.
Market Breakup by Region
The segmentation based on the region covers the United States, EU-4 (Germany, France, Italy, Spain), and the United Kingdom, Japan, and India. North America holds a substantial fibrotic diseases treatment market value which can be attributed to the rising geriatric population base in the region. Moreover, the high prevalence rate of fibrotic diseases and the presence of key market players are also boosting growth in this regional market.
The key features of the market report include patent analysis, grants analysis, clinical trials analysis, funding and investment analysis, partnerships, and collaborations analysis by the leading key players. The major companies in the market are as follows:
Kindly note that this only represents a partial list of companies, and the complete list has been provided in the report.
Upto 15% Off
USD
$3299 $2969
$5499 $4949
$6999 $5949
$8199 $6969
*While we strive to always give you current and accurate information, the numbers depicted on the website are indicative and may differ from the actual numbers in the main report. At Expert Market Research, we aim to bring you the latest insights and trends in the market. Using our analyses and forecasts, stakeholders can understand the market dynamics, navigate challenges, and capitalize on opportunities to make data-driven strategic decisions.*
Get in touch with us for a customized solution tailored to your unique requirements and save upto 35%!
The market is anticipated to grow at a CAGR of 7.60% during the forecast period of 2026-2035, the rising prevalence and incidence of fibrotic diseases across the 8 major markets.
The rapid advancement in the treatment of fibrotic diseases, growing preference for precision medicine, and heightened patient awareness are fuelling the demand for the market.
One of the significant trends in the market is the growth in clinical trials aimed at developing innovative and effective treatment therapies. In September 2023, Boehringer Ingelheim initiated the clinical development of its first-of-its-kind IL-11 inhibitor antibody, BI 765423, through a Phase 1 study. The objective of the trial is to evaluate the treatment's safety, tolerance, and pharmacokinetics in fibrotic diseases.
Based on the treatment type, the market is segmented into medication, organ transplantation, and oxygen therapy, among others.
Major end users of the market include hospitals, academic, and research institutes, among others.
Common applications areas include idiopathic pulmonary fibrosis (IPF), hepatic cirrhosis, renal fibrosis, cutaneous fibrosis, and others.
The major regions of the market include the United States, EU-4 (Germany, France, Italy, Spain), United Kingdom, Japan, and India.
Key players involved in the market are Genentech, Inc., Boehringer Ingelheim International GmbH, AbbVie Inc., Bristol-Myers Squibb Company, BellBrook Labs, Enveda Biosciences, Gilead Sciences, Inc., KITHER BIOTECH S.R.L., Verona Pharma plc, Alpine Immune Sciences, Intercept Pharmaceuticals, Inc., Teva Pharmaceutical Industries Ltd., Sandoz International GmbH, and Accord Healthcare.
Explore our key highlights of the report and gain a concise overview of key findings, trends, and actionable insights that will empower your strategic decisions.
| REPORT FEATURES | DETAILS |
| Base Year | 2025 |
| Historical Period | 2019-2025 |
| Forecast Period | 2026-2035 |
| Scope of the Report |
Historical and Forecast Trends, Industry Drivers and Constraints, Historical and Forecast Market Analysis by Segment:
|
| Breakup by Treatment Type |
|
| Breakup by Applications |
|
| Breakup by End User |
|
| Breakup by Region |
|
| Market Dynamics |
|
| Competitive Landscape |
|
| Companies Covered |
|
Datasheet
One User
USD 3,299
USD 2,969
tax inclusive*
Single User License
One User
USD 5,499
USD 4,949
tax inclusive*
Five User License
Five User
USD 6,999
USD 5,949
tax inclusive*
Corporate License
Unlimited Users
USD 8,199
USD 6,969
tax inclusive*
*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*
Flash Bundle
Small Business Bundle
Growth Bundle
Enterprise Bundle
*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*
Flash Bundle
Number of Reports: 3
20%
tax inclusive*
Small Business Bundle
Number of Reports: 5
25%
tax inclusive*
Growth Bundle
Number of Reports: 8
30%
tax inclusive*
Enterprise Bundle
Number of Reports: 10
35%
tax inclusive*
How To Order
Select License Type
Choose the right license for your needs and access rights.
Click on ‘Buy Now’
Add the report to your cart with one click and proceed to register.
Select Mode of Payment
Choose a payment option for a secure checkout. You will be redirected accordingly.
Gain insights to stay ahead and seize opportunities.
Get insights & trends for a competitive edge.
Track prices with detailed trend reports.
Analyse trade data for supply chain insights.
Leverage cost reports for smart savings
Enhance supply chain with partnerships.
Connect For More Information
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
We employ meticulous research methods, blending advanced analytics and expert insights to deliver accurate, actionable industry intelligence, staying ahead of competitors.
Our skilled analysts offer unparalleled competitive advantage with detailed insights on current and emerging markets, ensuring your strategic edge.
We offer an in-depth yet simplified presentation of industry insights and analysis to meet your specific requirements effectively.
Share